Literature DB >> 24975529

Quality bowel preparation for surveillance colonoscopy in patients with inflammatory bowel disease is a must.

Andrew Nett1, Fernando Velayos1, Kenneth McQuaid2.   

Abstract

Colonoscopy is routinely performed in patients with inflammatory bowel disease (IBD) for surveillance of dysplasia. Thorough bowel preparation is necessary to facilitate lesion detection. Patients with IBD do not have poorer bowel preparation outcomes but may have decreased preparation tolerance affecting adherence to surveillance protocols. A low-fiber prepreparation diet may improve preparation tolerance without affecting preparation quality. The standard preparation regimen should consist of split-dose administration of a polyethylene glycol-based purgative. Low-volume, hyperosmolar purgatives may be considered in patients with previous preparation intolerance, heightened anxiety, stenotic disease, or dysmotility. Appropriate patient education is critical to enhance preparation quality. Published by Elsevier Inc.

Entities:  

Keywords:  Bowel preparation; Dysplasia surveillance; Inflammatory bowel disease

Mesh:

Substances:

Year:  2014        PMID: 24975529     DOI: 10.1016/j.giec.2014.03.004

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  5 in total

Review 1.  Which Patient-Related Factors Determine Optimal Bowel Preparation?

Authors:  Myriam Martel; Charles Ménard; Sophie Restellini; Omar Kherad; Majid Almadi; Maïté Bouchard; Alan N Barkun
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

2.  Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy.

Authors:  Anand Kumar; Vinayak Shenoy; Megan C Buckley; Laura Durbin; James Mackey; Anjali Mone; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2022-05-27       Impact factor: 3.487

Review 3.  Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease.

Authors:  Sophie Restellini; Omar Kherad; Talat Bessissow; Charles Ménard; Myriam Martel; Maryam Taheri Tanjani; Peter L Lakatos; Alan N Barkun
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

4.  Real-world comparison of the effectiveness and safety of different bowel preparation agents.

Authors:  Naomi C Sacks; Abhishek Sharma; Philip L Cyr; Gerald Bertiger; David N Dahdal; Stuart P Brogadir
Journal:  Clin Exp Gastroenterol       Date:  2018-08-16

5.  Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

Authors:  Waled Mohsen; Astrid-Jane Williams; Gabrielle Wark; Alexandra Sechi; Jenn-Hian Koo; Wei Xuan; Milan Bassan; Watson Ng; Susan Connor
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.